From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

How I treat HLH-like toxicities following immune effector cell therapy

Last Updated: Friday, April 17, 2026

Clinicians discuss their collective approach as well as the current treatment landscape for two CAR-associated hemophagocytic lymphohistiocytosis (HLH)–like toxicity syndromes: cytokine release syndrome with multiorgan dysfunction and immune effector cell–associated HLH-like syndrome.

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Translational Oncology

Development and characterization of anti-CXCR4 chimeric antigen receptor T cells

Blood

How I treat HLH-like toxicities following immune effector cell therapy

Immunology

Strategies of AI-driven CAR-T cell therapy towards solid tumours

British Journal of Clinical Pharmacology

Efficacy, safety and cost-effectiveness of CAR-T therapy

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Fast Facts #12: BCMA Targets